SOURCE: Frost & Sullivan

Frost & Sullivan

September 05, 2011 04:57 ET

Frost & Sullivan Honours Advanced Medical Diagnostics With Technology Innovation Award for HistoScanning™

Innovative HistoScanning™ Offers Clinical and Cost Benefits in Area of Prostate Cancer Detection

LONDON--(Marketwire - Sep 5, 2011) - The 2011 Frost & Sullivan Europe Technology Innovation Award in Ultrasound Imaging for prostate cancer is presented to Advanced Medical Diagnostics SA (AMD) for the development and commercialisation of a new technology called HistoScanning™.

In comparison to competing technologies, HistoScanning™ addresses the clinical requirement for tissue characterisation. Its first commercially available application is in the management of prostate cancer patients.

"Prostate HistoScanning™ is an innovative ultrasound based application that utilises advanced tissue characterisation algorithms to visualise the position and extent of tissue suspected of being malignant in the prostate gland," explains Frost & Sullivan Research Analyst Darshana De. "In this respect, its design is quite unique and superior to other ultrasound based technologies."

Moreover, in comparison to magnetic resonance imaging (MRI), cancer detection by HistoScanning™ seems very promising. In addition to the benefits of accessibility and usability, clinical studies have shown that Prostate HistoScanning™, compared to histopathology as the reference test, detects cancer lesions ≥ 0.20 cc with sensitivity of 93%.

"Prostate HistoScanning™ offers the simplicity of ultrasound and results that are comparable to MRI in a format that can be made available to all patients in the physician's office," notes De. "As an ultrasound based tissue characterisation technology, HistoScanning™ is accessible to the clinician in his office, as part of the routine workflow and for a wide range of applications."

The adoption of Prostate HistoScanning™ is poised to lead to a significant change in biopsy practice with urologists being able to select patients for biopsy and to direct biopsies to those areas of the gland that are likely to contain the malignant tissue.

In breast cancer and other solid tumours, HistoScanning™ will allow radiologists to distinguish more accurately between cancerous and benign tissue. Consequently, fewer patients will have an equivocal scanning result, which may have to be followed up by invasive diagnostic procedures.

"For all cancer patients, being able to follow up the effectiveness of treatment in a non invasive way opens up the possibility of a better quality of life and better treatment outcome," remarks De. "This technology is serving an unmet need in the management of cancer patients and therefore has the potential to significantly change the current clinical pathway and reduce overall costs."

Since its introduction, more than 7000 patients have undergone Prostate HistoScanning™ in the Europe Union (EU). Data collected on Prostate HistoScanning™ indicate that its use can reduce the number of prostate biopsies by 30%, with benefits to the patient and cost savings to the health system.

"For surgical procedures, data collected has shown that the very modest investment in Prostate HistoScanning™ can lead to significant cost savings in terms of the need for patients to undergo expensive salvage therapy," concludes De.

The Technology Innovation Award is presented to the company that has excelled in the following criteria: uniqueness of technology, impact on new products/applications, impact on functionality, impact on customer value and relevance of innovation to industry.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Advanced Medical Diagnostics SA (AMD)

Advanced Medical Diagnostics is a privately held company based in Waterloo, Belgium. The company is dedicated to improve cancer patient management in a clinically meaningful and cost effective manner. A dynamic and culturally diverse team of experienced scientists, engineers and business professionals is committed to bringing HistoScanning™ to medical specialists and their patients around the world.
HistoScanning™ is a trademark of Advanced Medical Diagnostics SA/NV, Waterloo, Belgium
For further information please visit

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit

Contact Information